Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 2/20 | 0.32 |
| ▸ | SKP1 | P63208 | 2/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258691 | 0.94 | CKS1B (0.33) | CYP11B2CKS1BSKP1SKP2RET | |
| SCHEMBL21258946 | 0.93 | CKS1B (0.33) | CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL21258992 | 0.92 | CKS1B (0.33) | CYP11B2CKS1BSKP1SKP2RET | |
| SCHEMBL21258939 | 0.91 | CKS1B (0.38) | CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL21258669 | 0.90 | AKT1 (0.33) | RETNR1H4AKT1 | |
| SCHEMBL21258967 | 0.89 | CKS1B (0.34) | CYP11B2CKS1BSKP1SKP2RET | |
| SCHEMBL21258681 | 0.87 | CKS1B (0.34) | CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL22781926 | 0.87 | MEN1 (0.35) | CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL21258886 | 0.86 | MEN1 (0.35) | CYP11B2CKS1BSKP1SKP2 | |
| SCHEMBL21258952 | 0.86 | PTGIR (0.37) | CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | CYP11B2 58/4885CKS1B 3575/4885SKP1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.